Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Short Interest Update

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 145,500 shares, a growth of 63.3% from the October 31st total of 89,100 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average daily volume of 340,600 shares, the short-interest ratio is presently 0.4 days.

Protagenic Therapeutics Price Performance

PTIX stock opened at $0.59 on Friday. Protagenic Therapeutics has a 1 year low of $0.49 and a 1 year high of $1.87. The firm has a 50-day moving average of $0.62 and a 200 day moving average of $0.79. The company has a market cap of $4.01 million, a P/E ratio of -0.46 and a beta of 0.24.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.